Your browser doesn't support javascript.
loading
Can solid phase assays be better utilized to measure efficacy of antibody removal therapies?
Tambur, Anat R; Glotz, Denis; Herrera, Nancy D; Chatroop, Erik N; Roitberg, Tal; Friedewald, John J; Gjertson, David.
Afiliación
  • Tambur AR; Transplant Immunology Laboratory, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: a-tambur@northwestern.edu.
  • Glotz D; Nephrology and Transplantation Service, Hôpital Saint-Louis, Paris, France.
  • Herrera ND; Transplant Immunology Laboratory, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Chatroop EN; Transplant Immunology Laboratory, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Roitberg T; Transplant Immunology Laboratory, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Friedewald JJ; Department of Medicine, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Gjertson D; Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, USA.
Hum Immunol ; 77(8): 624-630, 2016 Aug.
Article en En | MEDLINE | ID: mdl-27267046
Antibody removal therapies are used for patients with antibody-mediated-rejection or those requiring desensitization to become transplantable. Accurate measurement of antibody levels prior to, and during treatment, are required to choose the best therapeutic approach, and to provide measure of treatment efficacy. Currently, the FDA does not regard solid-phase assays for HLA-antibody identification as a reliable surrogate-marker for treatment efficacy. Serum samples from 40 patients (58 assays; >2200 positive data points) undergoing antibody-removal-therapies were tested as sample-pairs, pre- and post-treatment. MFI values of IgG and C1q single-antigen-bead assays were compared with antibody titer values (serial dilutions). Antibody reduction was tracked and the differences in pre-to-post-treatment values were calculated as delta-reduction of antibody levels. Dynamic patterns of titration studies reduced effects of serum-inherent inhibitory factors (prozone-like); eliminated over-saturation limitations, and provided better estimation of antibody-binding strength compared with the other methods. Moreover, delta-reduction of antibody values using titration studies was significantly more uniform compared with either IgG or C1q tests. Analyzing antibody results using only C1q positive or only higher MFI values did not change the overall magnitude of results. Overall, titration studies provided better estimate of responsiveness to treatment and thus can serve as companion to monitoring efficacy of antibody-removal therapies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Técnicas de Inmunoadsorción / Trasplante de Riñón / Plasmaféresis / Rechazo de Injerto / Isoanticuerpos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hum Immunol Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Técnicas de Inmunoadsorción / Trasplante de Riñón / Plasmaféresis / Rechazo de Injerto / Isoanticuerpos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hum Immunol Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos